CD8A and neoplasm: Compared with vehicle control, ATRi QDx3 plus RT increased proliferating CD8+ T cells (as a percentage of live, CD45+ immune cells) in the DLN and TILs of B16 tumor–bearing mice, while ATRi QDx9 plus RT did not (Figure 7E).